Rivus Pharmaceuticals Inc. has emerged from stealth and disclosed a $35 million series A round to fund development of its pipeline of “controlled metabolic accelerators,” or CMAs, for treating cardiometabolic diseases.
French biotech Pep-Therapy SAS is taking its potentially first-in-class cancer cell penetrating peptide technology into the clinic, after raising €5.4 million (US$6.4 million) in an extended series A funding round. The series A fundraiser initially brought in €2.6 million, but the extension brought in a further €1.6 million in equity from Anaxago, i&i Prague and Badge as well as a €1 million loan from Bpifrance.
Myopia, or near-sightedness, is a growing public health problem, often beginning in childhood. Severe cases can lead to serious complications including cataract, glaucoma and retinal detachment. Now, Dopavision GmbH has raised a €12 million (US$14.2 million) series A round to advance its digital childhood myopia therapeutic aimed at nipping this lifelong problem in the bud.
Paq Therapeutics Inc. closed a $30 million series A round to take forward a novel approach to the targeted degradation and removal of a wide range of molecular substrates and defective organelles by developing drug molecules that can tap into autophagy, the cell’s general waste disposal and recycling system.
Prime Medicine Inc. (PM) likely has “a lock on prime editing technology for therapeutic uses,” CEO Keith Gottesdiener told BioWorld, though research labs are continuing to refine the approach. Cambridge, Mass.-based PM has $315 million in the bank that will help advance the platform, which behaves like a DNA word processor to search and replace disease-causing genetic sequences at their exact location in the genome.
LONDON – Neuvasq Biotechnologies has launched with a €20 million (US$23.7 million) series A to take forward a new approach to treating neurological disorders by reversing age- or injury-related damage to the blood-brain barrier.
Xilis Inc. closed $70 million in series A financing on July 8 to reduce drug development costs leveraging its technology, with the goal of advancing precision medicine through targeted drug discovery and development. The financing was led by Mubadala Capital with participation from new investors that include GV, formerly Google Ventures, and others.
LONDON – Another Novo Seeds start-up has graduated, with Muna Therapeutics ApS closing a $73 million series A to take forward small-molecule treatments for neurodegenerative diseases.
Arrivent Biopharma Inc. has raised a series A financing worth up to $150 million to in-license compounds from China and bring them to the rest of the world. Arrivent’s focus is in oncology and its first in-licensed asset is furmonertinib, a third-generation EFGR tyrosine kinase inhibitor from Shanghai-based Allist Pharmaceuticals Co. Ltd.
Arrivent Biopharma Inc. has raised a series A financing worth up to $150 million to in-license compounds from China and bring them to the rest of the world. Arrivent’s focus is in oncology and its first in-licensed asset is furmonertinib, a third-generation EFGR tyrosine kinase inhibitor from Shanghai-based Allist Pharmaceuticals Co. Ltd.
RSS
